Ramses Fernandez Melo, MD
Neurology · Fort Myers, FLNPI 1144789900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,250 of the $3,506 with a category attached, or 64.2%. 20 manufacturers reported payments, led by UCB, Inc. at 43.0% of the total. Reporting peaked in 2023 at $1,571 and has fallen 83.0% since, to $267 in 2025.
Across 48 payments — averaging $73.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Neurocrine Biosciences, Inc.$455
- Amneal Pharmaceuticals LLC$242
- AbbVie$207
- Biogen$176
- SK Life Science, Inc.$149
- plus $770 from 14 others
Across 265 payments — averaging $2099.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$291K
- Biohaven Pharmaceutical Holding Company Ltd.$220K
- Genentech, Inc.$46K
What the payments were for
- Speaking & faculty fees$2427%
- Travel & lodging$1,01429%
- Food & beverage$2,25064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 12 | $1,506 |
| Neurocrine Biosciences, Inc. | 4 | $455 |
| Amneal Pharmaceuticals LLC | 2 | $242 |
| AbbVie | 9 | $207 |
| Biogen | 2 | $176 |
| SK Life Science, Inc. | 2 | $149 |
| Neurelis, Inc. | 2 | $138 |
| Abbott | 1 | $130 |
| Kyowa Kirin, Inc. | 1 | $116 |
| EMD Serono, Inc. | 1 | $109 |
| NS Pharma, Inc. | 1 | $53 |
| Lilly USA, LLC | 2 | $45 |
| Aquestive Therapeutics, Inc. | 2 | $43 |
| Greenwich Biosciences, Inc. | 1 | $29 |
| Argenx US, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,506 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Fort Myers
- Gustavo SilvaFort Myers$165K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.